BioGaia AB (publ) (BGLAF)
| Market Cap | 1.28B +22.6% |
| Revenue (ttm) | 165.73M +13.1% |
| Net Income | 39.22M +23.9% |
| EPS | 0.39 +24.2% |
| Shares Out | n/a |
| PE Ratio | 29.26 |
| Forward PE | 26.84 |
| Dividend | 0.43 (3.76%) |
| Ex-Dividend Date | May 8, 2026 |
| Volume | 100 |
| Open | 11.55 |
| Previous Close | 12.20 |
| Day's Range | 11.55 - 11.55 |
| 52-Week Range | 10.24 - 12.20 |
| Beta | 0.23 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 22, 2026 |
About BioGaia AB
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablet... [Read more]
Financial Performance
In 2025, BioGaia AB's revenue was 1.54 billion, an increase of 8.11% compared to the previous year's 1.42 billion. Earnings were 332.76 million, a decrease of -5.30%.
Financial numbers in SEK Financial StatementsNews
BioGaia AB Earnings Call Transcript: Q3 2026
Q3 sales rose 23% to SEK 400m and EBIT margin reached 33%, with double-digit growth in both segments and all regions. Management expects strong Q4 Asia Pacific growth, while substantial EMEA pediatric orders shifted from Q4 into Q3.
BioGaia AB Quarterly report: Q3 2026
BioGaia AB has published its Q3 2026 quarterly earnings report on October 22, 2026.
BioGaia AB Slides: Q3 2026
BioGaia AB has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 22, 2026.
BioGaia AB Earnings Call Transcript: Q2 2026
Organic sales grew 12% year-over-year in Q2, with EBIT margin rising to 30% and adjusted EBIT at 33%. EMEA and Americas saw strong growth, while Asia Pacific declined due to order variability. Investments in capacity and direct markets continue, with China sales expected to rebound in H2.
BioGaia AB Quarterly report: Q2 2026
BioGaia AB has published its Q2 2026 quarterly earnings report on July 17, 2026.
BioGaia AB Slides: Q2 2026
BioGaia AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 17, 2026.
BioGaia AB Earnings Call Transcript: Q1 2026
Organic growth reached 15% year-over-year, driven by strong direct market performance and new product launches. EBIT margin remained at 27%, with double-digit growth in both pediatric and adult segments. Currency effects weighed on reported growth and gross margin.
BioGaia AB Quarterly report: Q1 2026
BioGaia AB has published its Q1 2026 quarterly earnings report on May 7, 2026.
BioGaia AB Slides: Q1 2026
BioGaia AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
BioGaia AB Earnings Call Transcript: Q4 2025
Q4 organic sales grew 32% and full-year 2025 organic growth reached 14%, with strong gains in direct markets and new product launches. EBIT margin was 27% for Q4, and a total dividend of SEK 4 per share is proposed.
BioGaia AB Annual report: Q4 2025
BioGaia AB has published its Q4 2025 annual report on February 12, 2026.
BioGaia AB Quarterly report: Q4 2025
BioGaia AB has published its Q4 2025 quarterly earnings report on February 12, 2026.
BioGaia AB Slides: Q4 2025
BioGaia AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 12, 2026.